SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT : vimarsana.com

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Dublin , Ireland , Reggio Emilia , Emilia Romagna , Italy , London , City Of , United Kingdom , Sanofi Genzyme , Dirk Kersten , Dennis Riedl , Ray Barlow , Jon Edwards , Carlo Incerti , Prnewswire Synox Therapeutics Limited , Synox Therapeutics , University Of Modena , University Of North Carolina , Phathom Pharmaceuticals , Checkmate Pharmaceuticals , Bioqube Ventures , Tenosynovial Giant Cell Tumour , Chief Executive Officer , General Partner , Forbion Growth , Non Executive Chair , Associate Professor , Numab Therapeutics , Vectory Therapeutics , Managing Director , Red Tree Venture Capital , Impact Biomedicines , North Carolina , Giant Cell Tumour , Aktien Sie ,